TRANSLATE

The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Highlights from the first virtual COMy meeting

By Claire Baker

Share:

Featured:

Mohamad MohtyMohamad Mohty

May 28, 2020


During COMy 2020, Mohamad Mohty, Saint-Antoine Hospital and Sorbonne University, Paris, FR, discussed highlights from the first virtual COMy meeting.

Professor Mohty outlined the controversial debates that took place during the virtual meeting. Debate topics included the treatment of elderly patients with multiple myeloma, the prognostic value of minimal residual disease to guide treatment decisions, and the routine incorporation of anti-CD38 monoclonal antibodies into induction regimens. A hot topic of the COMy 2020 online meeting was the question of whether or not to proceed with transplant, and professor Mohty concluded with a personal opinion on the matter.

Highlights from the first virtual COMy meeting

More about...